Prenetics Pivots to IM8, Posts 480% Revenue Surge on Quarterly Subscription Shift
Event summary
- Prenetics reported FY2025 revenue of $92.4M, up 480% YoY, driven by IM8's $60.1M contribution.
- IM8 achieved $120M ARR in 12 months, with Q4 monthly revenue hitting $10M.
- Company completed strategic divestitures, including Insighta stake sale to Tencent for $70M.
- Quarterly subscription model boosted average order value to $233 in early 2026.
- Adjusted liquidity stands at $171M with zero debt as of February 2026.
The big picture
Prenetics' strategic pivot to IM8 reflects the accelerating consolidation in consumer health, where premium subscription models are becoming the norm. The company's ability to monetize celebrity partnerships and global sports endorsements will be key to maintaining its competitive edge. With $171M in adjusted liquidity and zero debt, Prenetics has positioned itself for aggressive growth, but must prove it can convert revenue gains into sustainable profitability.
What we're watching
- Execution Risk
- Whether Prenetics can sustain IM8's rapid growth trajectory while maintaining unit economics.
- Market Expansion
- The pace at which IM8 can scale internationally beyond its current 30+ countries.
- Profitability Timing
- How quickly Prenetics can achieve adjusted EBITDA profitability by Q4 2027.
Related topics